Intensified inhibition of renin-angiotensin system: A way to improve renal protection?

Paolo Cravedi, Piero Ruggenenti, Giuseppe Remuzzi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Several large, randomized, multicenter studies in diabetic and nondiabetic patients with chronic proteinuric nephropathies have clearly demonstrated that angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARB) are able to reduce urinary protein excretion and retard renal disease progression. However, the number of patients who reach end-stage renal failure is still considerable and there is a great need to identify therapies that can arrest evolution of kidney damage. Maximizing renin-angiotensin system (RAS) blockade through combined ACE inhibitor and ARB therapy has been shown to further increase antiproteinuric and nephroprotective effects of each drug class. However, in order to slow to the greatest extent progression of renal disease, the ideal therapeutic approach for patients with proteinuric nephropathies should be a multimodal strategy including dual RAS blockade, antialdosterone therapy, lipid-lowering agents, smoking cessation, and tight glucose control for diabetes.

Original languageEnglish
Pages (from-to)118-124
Number of pages7
JournalCurrent Hypertension Reports
Volume11
Issue number2
DOIs
Publication statusPublished - 2009

Fingerprint

Renin-Angiotensin System
Kidney
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Disease Progression
Smoking Cessation
Therapeutics
Multicenter Studies
Chronic Kidney Failure
Lipids
Glucose
Inhibition (Psychology)
Pharmaceutical Preparations
Proteins

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Intensified inhibition of renin-angiotensin system : A way to improve renal protection? / Cravedi, Paolo; Ruggenenti, Piero; Remuzzi, Giuseppe.

In: Current Hypertension Reports, Vol. 11, No. 2, 2009, p. 118-124.

Research output: Contribution to journalArticle

@article{f3b50efae7ca4d3e8a5a6a64158397c6,
title = "Intensified inhibition of renin-angiotensin system: A way to improve renal protection?",
abstract = "Several large, randomized, multicenter studies in diabetic and nondiabetic patients with chronic proteinuric nephropathies have clearly demonstrated that angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARB) are able to reduce urinary protein excretion and retard renal disease progression. However, the number of patients who reach end-stage renal failure is still considerable and there is a great need to identify therapies that can arrest evolution of kidney damage. Maximizing renin-angiotensin system (RAS) blockade through combined ACE inhibitor and ARB therapy has been shown to further increase antiproteinuric and nephroprotective effects of each drug class. However, in order to slow to the greatest extent progression of renal disease, the ideal therapeutic approach for patients with proteinuric nephropathies should be a multimodal strategy including dual RAS blockade, antialdosterone therapy, lipid-lowering agents, smoking cessation, and tight glucose control for diabetes.",
author = "Paolo Cravedi and Piero Ruggenenti and Giuseppe Remuzzi",
year = "2009",
doi = "10.1007/s11906-009-0022-9",
language = "English",
volume = "11",
pages = "118--124",
journal = "Current Hypertension Reports",
issn = "1522-6417",
publisher = "Current Medicine Group",
number = "2",

}

TY - JOUR

T1 - Intensified inhibition of renin-angiotensin system

T2 - A way to improve renal protection?

AU - Cravedi, Paolo

AU - Ruggenenti, Piero

AU - Remuzzi, Giuseppe

PY - 2009

Y1 - 2009

N2 - Several large, randomized, multicenter studies in diabetic and nondiabetic patients with chronic proteinuric nephropathies have clearly demonstrated that angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARB) are able to reduce urinary protein excretion and retard renal disease progression. However, the number of patients who reach end-stage renal failure is still considerable and there is a great need to identify therapies that can arrest evolution of kidney damage. Maximizing renin-angiotensin system (RAS) blockade through combined ACE inhibitor and ARB therapy has been shown to further increase antiproteinuric and nephroprotective effects of each drug class. However, in order to slow to the greatest extent progression of renal disease, the ideal therapeutic approach for patients with proteinuric nephropathies should be a multimodal strategy including dual RAS blockade, antialdosterone therapy, lipid-lowering agents, smoking cessation, and tight glucose control for diabetes.

AB - Several large, randomized, multicenter studies in diabetic and nondiabetic patients with chronic proteinuric nephropathies have clearly demonstrated that angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARB) are able to reduce urinary protein excretion and retard renal disease progression. However, the number of patients who reach end-stage renal failure is still considerable and there is a great need to identify therapies that can arrest evolution of kidney damage. Maximizing renin-angiotensin system (RAS) blockade through combined ACE inhibitor and ARB therapy has been shown to further increase antiproteinuric and nephroprotective effects of each drug class. However, in order to slow to the greatest extent progression of renal disease, the ideal therapeutic approach for patients with proteinuric nephropathies should be a multimodal strategy including dual RAS blockade, antialdosterone therapy, lipid-lowering agents, smoking cessation, and tight glucose control for diabetes.

UR - http://www.scopus.com/inward/record.url?scp=62549163397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62549163397&partnerID=8YFLogxK

U2 - 10.1007/s11906-009-0022-9

DO - 10.1007/s11906-009-0022-9

M3 - Article

C2 - 19278601

AN - SCOPUS:62549163397

VL - 11

SP - 118

EP - 124

JO - Current Hypertension Reports

JF - Current Hypertension Reports

SN - 1522-6417

IS - 2

ER -